VYGR News

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective small molecules for people suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology. TDP-43 pathology is common in many neurodegenerative diseases, including over 90% of ALS cases1 and up to 45% of FTD cases2.

(NASDAQ:VYGR) HOUSTON and OXFORD, England, Sept. 2, 2025 /PRNewswire/ -- Velocys, a leader in Fischer-Tropsch (FT) technology for the production of sustainable aviation fuel (SAF) and other low-carbon fuels, today announced that it has signed an agreement with Morimatsu to provide manufacturing and...

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

DENVER--(BUSINESS WIRE)--Voyager appoints Paul Tilghman as Chief Technology Officer.

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -